Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRIM24 | O15164 | 2/20 | 0.45 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7272667 | 0.97 | TRIM24 (0.48) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL4838366 | 0.92 | — | — | |
| Cyclopentanone SCHEMBL28195072 | 0.83 | TRIM24 (0.59) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL7092089 | 0.80 | TRIM24 (0.30) | TRIM24TRIM33 | |
| SCHEMBL561522 | 0.80 | — | — | |
| SCHEMBL11532547 | 0.75 | TRIM24 (0.53) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL7093394 | 0.74 | — | — | |
| SCHEMBL6653639 | 0.72 | TRIM24 (0.43) | TRIM24TRIM33ALDH1A1 | |
| SCHEMBL27628200 | 0.69 | — | — | |
| SCHEMBL4730800 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1247593-C | Thiepino [3, 2-b ] dihydropyridines and related compositions and methods | ORTHO MCNEIL PHARM INC (US) | 2006-03-29 | — | — | CN | disclosed |
| CN-1522257-A | Thiepino[3,2-b]dihydropyridines and related compositions and methods | ����-������ҩƷ��˾ | 2004-08-18 | — | — | CN | disclosed |
| EP-1265903-B1 | THIEPINO[3,2-B]DIHYDROPYRIDINES AND RELATED COMPOSITIONS AND METHODS | ORTHO MCNEIL PHARM INC (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-1040097-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2004-04-14 | — | — | EP | disclosed |
| US-6593335-B1 | Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's | ABBOTT LABORATORIES | 2003-07-15 | — | — | US | disclosed |
| US-6420383-B1 | CALCIUM CHANNEL BLOCKERS, HYPERSENSITIVITY, ALLERGY, ASTHMA, BRONCHOSPASM, DYSMENORRHEA, ESOPHAGEAL SPASM, GLAUCOMA, PREMATURE LABOR, URINARY TRACT DISORDERS, GASTROINTESTINAL MOTILITY DISORDERS AND CARDIOVASCULAR DISORDERS. | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-07-16 | — | — | US | disclosed |
| EP-1194429-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-10 | — | — | EP | disclosed |
| US-20010036950-A1 | Potassium channel openers | CARROLL WILLIAM A (US) | 2001-11-01 | — | — | US | disclosed |
| US-6265417-B1 | MUSCLE RELAXANTS | ABBOTT LABORATORIES | 2001-07-24 | — | — | US | disclosed |
| WO-2000078768-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040097-A1 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2000-10-04 | — | — | EP | disclosed |
| WO-1999031059-A1 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 1999-06-24 | — | — | WO | disclosed |
| EP-0241281-B1 | Substituted thiacycloalkeno [3,2-b] pyridines, methods of preparation, compositions and method of use | ORTHO PHARMA CORP (US) | 1994-07-27 | — | — | EP | disclosed |
| US-4879384-A | CYCLIC THIAALKANONE DIOXIDE AND UNSATURATED AMINE ESTER | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-11-07 | — | — | US | disclosed |
| US-4845225-A | CARDIOVASCULAR, ANTIASTHMATIC AND ANTIBRONCHOCONSTRICTOR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-07-04 | — | — | US | disclosed |
| US-4777167-A | CALCIUM CHANNEL ANTAGONIST, ANTICOAGULANTS, ANTIASTHMATIC, BRONCHODILATOR AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-10-11 | — | — | US | disclosed |
| US-4705785-A | Substituted thiacycloalkeno (3,2-b) pyridines and pharmaceutical compositions and method of use | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-11-10 | — | — | US | disclosed |
| EP-0241281-A2 | Substituted thiacycloalkeno [3,2-b] pyridines, methods of preparation, compositions and method of use | ORTHO PHARMACEUTICAL CORPORATION (US) | 1987-10-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010036950-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | TRIM24 3359/4885TRIM33 4469/4885ALDH1A1 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.